HIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
|
|
- Shavonne Greer
- 5 years ago
- Views:
Transcription
1 HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
2 Learning objectives Identify the optimal timing of antiretroviral therapy in patients with HIV/TB coinfection Recognize factors that influence the selection of optimal concurrent HAART regimens in HIV/TB coinfected patients Recognize and manage complications associated with concurrent treatment of HIV and TB
3 Case presentation 47-year old female presented with a 2-month history of abdominal pain, diarrhea, weight loss, cough, fever & night sweats. No significant past medical history No known TB exposure Born in Zimbabwe and moved to US 6 months prior to presentation Severe wasting, T o F,HR - 76, RR - 18, BP - 120/80.
4 Case presentation
5 Case presentation Sputum was AFB smear positive and eventually grew M. tuberculosis Rifampin, Isoniazid, Pyrazinamide and Ethambutol started and HIV test sent HIV test - positive, CD4-63 cells/µl (1.8%), HIV-1 RNA level 435,000 copies/ml. Bactrim DS one daily and fluconazole 100 mg daily added to therapy
6 Clinical management issues When should HAART be initiated after starting TB treatment? What antiretroviral regimens can be used concurrently with TB therapy? Toxicities concerns and how should patient be managed?
7 EPIDEMIOLOGY OF HIV/TB COINFECTION
8
9 HIV/TB: Profound Effect on Individuals The annual risk of TB in HIV infected approximates the lifetime risk of HIV uninfected Small and Fujiwara, N Eng J Med 343:189, 2001
10 Estimated TB incidence (per 100,000 population) TB incidence closely correlated with HIV prevalence in Africa HIV prevalence, adults 15-49y WHO
11
12
13 RATIONALE FOR CONCURRENT THERAPY
14 TB death rates per HIV status, 2009 Numbers under bars indicate the number in each cohort, not evaluated outcomes not included 14 Collaborative TB/HIV activities, 2010
15 Effective TB treatment does not delay HIV disease progression 111 HIV-infected patients hospitalized with TB (12 died) HIV plasma load was high at baseline and remained high despite anti-tb therapy Anti-TB therapy had no significant influence on CD4+ cell count Morris L, et al. JID 2003;187:
16 HAART during TB treatment saves lives Concomitant HAART markedly improves survival in HIV-infected patients with HIV/TB coinfection. Manosuthi, W et al. JAIDS. 43(1):42-46
17 WHEN TO START ANTIRETROVIRAL THERAPY?
18 Integrated HIV and TB therapy is challenging Optimal timing of ART is unclear Immune restoration inflammatory syndrome (TB-IRIS) What regimens Overlapping drug toxicities Pharmacokinetic drug-drug interactions Implementation issues
19 Early versus delayed initiation of antiretroviral therapy during TB treatment Early ART (before 8 wks of TB treatment) Delayed ART (after 8 wks of TB treatment) Adherence demand Ability to determine the cause of adverse events Drug-drug interaction Severe immune reconstitution inflammatory events HIV disease progression (new OI or death Problematic with use of 4-drug for TB and multidrug therapy for HIV Complex because of the large number of medications started in a short time period and overlapping side effects profiles Problematic Risk may be increased Risk may be decreased Less problematic because fewer drugs necessary for TB treatment Simpler because the number of drugs for TB treatment is less and there has been more time to evaluate response to TB treatment Problematic Risk may be decreased Risk may be increased Burman WJ. Clin Chest Med 2005;26:
20 SAPiT study: integrated antiretroviral TB therapy improves survival Abdool Karim SS, et al. NEJM 2010;362:
21 Highlights of AIDS 2010 clinicaloptions.com/hiv CAMELIA: ART Initiation at Wk 2 vs Wk 8 of TB Therapy in HIV-Coinfected Patients WHO 2010 guidelines recommend to [1] Initiate HAART in all HIV-infected patients with TB, regardless of CD4+ cell count Initiate TB therapy before HAART, with HAART added as soon as possible and within 8 wks of TB therapy CAMELIA: randomized, open-label trial of HIV-infected patients with newly-diagnosed AFB-positive TB and CD4+ cell count 200 cells/mm 3 [2] Compared HAART initiation (d4t + 3TC + EFV) at Wk 2 (n = 332) vs Wk 8 (n = 329) of TB therapy All patients received standard TB therapy for 6 mos 1. WHO. Available at: 2. Blanc FX, et al. AIDS Abstract THLBB106.
22 Probability of Survival Highlights of AIDS 2010 clinicaloptions.com/hiv CAMELIA: Survival With Early vs Late Therapy in TB-Coinfected Patients Wk 50 Survival Probability, Early vs Late Therapy 1.00 Early arm 0.90 Late arm Log rank P = Wks From TB Treatment Initiation Survival Probability, % (95% CI) Early Arm 86.1 ( ) 82.6 ( ) 82.0 ( ) Late Arm 80.7 ( ) 73.0 ( ) 70.2 ( ) Blanc FX, et al. AIDS Abstract THLBB206. Graphic used with permission.. P Factors Independently Associated With Mortality Factor Multivariate Adjusted HR (95% CI) Late therapy 1.52 ( ).007 BMI ( ).01 Karnofsky score 40 Pulmonary + extrapulmonary TB Significantly higher incidence of IRIS with early vs late HAART 4.03 vs 1.44 per 100 person-mos, respectively (P <.0001) P 4.96 ( ) <.001` 2.26 ( ) <.001 NTM 2.84 ( ) <.001 MDR-TB 8.02 ( ) <.001
23 The STRIDE study: ACTG5221 Results: Proportion with AIDS/Death Immed. N=405 Early N=401 All 12.9% 16.1% 0.45 CD4< % 26.6% 0.02 CD4> % 10.3% 0.67 Nearly 70% enrolled from African sites Patients received Efavirenz + TDF/FTC Median (IQR) CD4 77 (36 145) P Randomized strategy trial of immediate (within 2 weeks) and early (8-12 weeks) PVL < 400 copies/ml was 74% and no diff between groups MTB IRIS was 11% in immediate and 5% in early group (P =0.002) Havlir D, et al. CROI 2011, Boston. Abstract # 38.
24 SAPiT Trial: Analysis of the integrated arm Results: Risk of AIDS or Death IRR (95% CI) All 0.89 ( ) 0.73 CD4< ( ) 0.06 CD4> ( ) 0.34 Done in South Africa All patients received Efavirenz + ddi/3tc Median (IQR) CD4 150 (77 254) Early (N=214); late (N=215) P Randomized study of early (within 4 weeks) and early (8-12 weeks) Over 90% achieved viral suppression after 18 months IRR (early vs. Late) for MTB IRIS was 4.7 and 2.2 for CD4< and >50, resp. Abdool Karim Q, et al. CROI 2011, Boston. Abstract # 39LB.
25 Challenges of immediate ART (within 2 weeks) in sub-saharan Africa Rapid HIV and TB diagnosis Rapid staging of HIV disease by CD4 count or by clinical criteria Integration of HIV and TB program to ensure availability of ART at site of diagnosis Prevention, early recognition and treatment of MTB IRIS Implementation issues with scale-up of intervention
26 WHAT ART REGIMEN?
27 INH, rifampin, PZA, and ethambutol (4 drugs, 10 pills once a day) Burman WJ. CFAR Symposium 2005, Boston
28 INH, rifampin, PZA, ethambutol, cotrimoxazole, AZT, 3TC, efavirenz (8 drugs, pills, 2-3 doses per day) Are you sure that I won t, like, blow up if I take all of these pills? Burman WJ. CFAR Symposium 2005, Boston
29 Rifampicin is an essential (crucial) component short-course chemotherapy Jindani A, et al. Lancet 2004; 364:
30 Rifampicin is a potent inducer of cytochrome P450 enzymes Niemi M, et al. Clin Pharmacokinet 2003;42: Rifampicin effect is variable Rifabutin has less induction effect on CYP3A4 Rifampicin is the only rifamycin readily available in TB endemic areas
31 DRUG DRUG P-gp * + DRUG * Portal blood + * * DRUG metabolite Enterocyte Systemic metabolite Hepatocyte *Rifamycins induces CYP systems and P-gp leading to increased metabolism and efflux of the PIs or NNRTIs. Rifampin >>> Rifabutin > rifapentine
32 Wilkinson GR. NEJM 2005; A. Mechanism of induction of CYP3A4- mediated metabolism of drug substrate B. The resulting reduced plasma drug concentration PXR Pregnane X receptor; RXR retinoid X receptor
33 Geiner B, et al. J Clin Invest 1999;104: a) Duodenal biopsy immunostained for P-gp before administration of rifampin b) biopsy after 9 days administration of rifampin 600mg daily
34 100 Decrease in serum concentrations (AUC) of HIV-1 protease inhibitors with rifampin or rifabutin With 100 mg RTV * * 20 0 ND 0 0 SQV RTV IDV NLV AMP LPV ATV Clin Infect Dis 1999; 28: Rifampin Rifabutin 12 th CROI, abstract 657
35 Decrease in serum concentrations (AUC) of nonnucleoside reverse-transcriptase inhibitors by rifampin or rifabutin NVP DLV EFV 0 Rifampin Rifabutin Clin Infect Dis 1999; 28:
36 HAART and rifampin-based TB treatment 2 NRTI/NtRTIs plus NNRTI or PI Recommended dose of ARVs with rifampin Efavirenz (preferred) 600 mg or?800 mg daily (BW > 60 kg) Nevirapine 200 mg bid with no lead in (or 300mg bid*) Saquinavir/ritonovir 400/400 mg bid or 1000/100 mg bid* Lopinavir/ritonovir 400/400 mg bid* Maraviroc 600 mg twice-daily (increased dose) Raltegravir 400 mg twice daily (no change) *use with caution CDC treatment guidelines for HIV-TB, Dec 2007
37 Interactions between efavirenz and rifampincontaining TB treatment Rifampin caused a decrease in: mean Cmax by 24% Cmin by 25% AUC by 22% Although minimal effective efavirenz plasma concentration that assures virological success is not currently known, it is advisable to increase dosage of efavirenz to 800 mg/day when coadministered with rifampin Lopez-Cortes LF, et al. Clin Pharmacokinet 2002;41:
38 Plasma EFV level (mg/l) EFV level in plasma (mg/l) Distribution of plasma EFV levels between EFV 600 and 800 mg groups (42 patients each) Figure 1a Efavirenz (EFV) level in plasma Figure 1b Plasma level of efavirenz (EFV) p = p = ns EFV 600 mg EFV 800 mg Dose per day 3.39 (median) 3.02 ( ) 10 p = ns ( ) p = EFV 600 mg EFV 800 mg dose per day Manosuthi W, et al. XV IAC 2004, Bangkook, Thailand; Manosuthi W et al. AIDS 2005;19:1481-6
39 Early virologic response to efavirenz-based therapy is not influenced by TB cotreatment Lartey M, et al. CID 2011;52:547-50
40 Genetic factors appear to be the key determinant of EFV during TB treatment EFV PK with TB therapy is influence by and host genetics. Kwara at al. JCP 2008; Paradoxical effect of TB therapy in slow metabolizers. Kwara at al. AIDS 2011;25:388
41 HAART and rifabutin-based TB treatment 2 NRTI/NtRTIs plus 3 rd ARV PI LPV/r, ATV/r, fapv/r, SQV/r (standard doses) Atazanavir 400 mg qd Fosamprenavir 1400 mg bid Indinavir 1000 mg tid Nelfinavir 1000 mg tid Maraviroc or raltegravir (no change) Rifabutin dose 150 mg qod or 300 mg 3X/W* 150 mg qd or 300 mg 3XW 150 mg qd or 300 mg 3XW 150 mg qd or 300 mg 3XW 150 mg qd or 300 mg 3XW No change *associated with TB treatment failure and rifamycin resistance
42 HAART and rifabutin-based TB treatment 2 NRTI/NtRTIs plus NNRTI NNRTI Nevirapine 200 mg bid Efavirenz 600 mg qd Rifabutin dose 300 mg qd or 300 mg 3X/week 600 mg qd or qod
43 Special population: Pregnant women and children Efavirenz is contraindicated during at least the first trimester of pregnancy Higher risk of hepatotoxicity in women with CD4 >250 cell/µl with nevirapine No drug-drug interaction studies in pregnant women Efavirenz should not be used in children younger than 3 years old. Limited drug-drug interactions studies in children Triple nucleoside therapy may be the only viable option in some children or pregnant where rifabutin is not available
44 Immune restoration inflammatory syndrome (TB-IRIS) Paradoxical worsening of TB symptoms on TB and ART or incident TB (unmasked TB) soon after starting ART in HIV-infected patients Continue concurrent therapy or continue appropriate ART and initiate TB therapy Symptomatic therapy with NSAIDs or steroids may be necessary
45 Summary The HIV-associated TB is associated with increased morbidity and mortality The timing of concurrent ART should be started as soon as TB therapy is tolerated Optimal ART regimen will depend on whether rifampin or rifabutin is used
46 Acknowledgements USAID and Higher Education for Development for grant support Associate award # AID-641-LA Lifespan/Tufts CFAR grant # P30AI from the National Institute of Allergy And Infectious Diseases Brown/Tufts AITRP Partner institutions, staff and faculty who have supported the partnership activities Medical knowledge FIESTA 2012 Organizers! THANK YOU FOR YOUR ATTENTION!
HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationApproach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationTB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationClinical Vignette: Patient 1. Approach to Co-infection with TB. TB and HIV Co-infection: Some Resources. Objectives.
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb AETC Natl Resource Center: http://www.aidsetc.org Approach to Co-infection with TB and HIV: 2012 Henry Fraimow, MD Consultant, Southern N.J.
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationTreating HIV and TB: New evidence, Challenges & Prospects
Treating HIV and TB: New evidence, Challenges & Prospects Pre-IAS International consultative meeting on Transforming the HIV/TB response: defining the next 10 years July 21 st, 2012 Moses R. Kamya Professor
More informationCLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb http://www.umdnj.edu/globaltb/coretbresources.htm Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J.
More information"Sterilization of TB disease in
11/1/1 "Sterilization of TB disease in mice " Jacques Grosset Pharmacodynamics of daily rifapentine and rifampin in mice Free rifam mycin Concentrati ion/mic 1 1 Rifapentine (1mg/kg) Free rifam mycin Concentrati
More informationTB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant
More informationDrug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
More informationHeidi Marie Soeters. Chapel Hill Approved by: Annelies Van Rie. Joseph Eron, Jr. Sonia Napravnik. Alan Brookhart.
THE EFFECT OF TUBERCULOSIS TREATMENT AT THE TIME OF COMBINATION ANTIRETROVIRAL THERAPY (CART) INITIATION ON RESPONSE TO CART AMONG HIV-INFECTED INDIVIDUALS Heidi Marie Soeters A dissertation submitted
More informationTuberculosis in AIDS Patients. Chien-Ching Hung Division of Infectious Diseases Department of Internal Medicine National Taiwan University Hospital
Tuberculosis in AIDS Patients Chien-Ching Hung Division of Infectious Diseases Department of Internal Medicine National Taiwan University Hospital Topics Epidemiology of TB in the era of HIV epidemic Impact
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationTuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009
TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationHIV: Approach to the Treatment-Naïve Patient
HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationTuberculosis and HIV
Julian Elliott National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Epidemiology Diagnosis of TB Clinical management Does this woman have tuberculosis? Estimated
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationDrug Interactions in TB / HIV Co-infected Patients
Drug Interactions in TB / HIV Co-infected Patients Saye Khoo HIV Pharmacology Group University of Liverpool / Biomedical Research Centre in Microbial Diseases HIV and TB prevalence Menu HIV TB drug interactions
More informationWhat is IRIS Types Outline of Presentation Principles behind Case definition of IRIS IRIS cause of early mortality IRIS a factor in optimal timing of
Immune Reconstitution Inflammatory Syndrome: A factor in Timing of Initiation of ART Yunus Moosa UKZN Durban South Africa What is IRIS Types Outline of Presentation Principles behind Case definition of
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationTuberculosis and HIV: key issues in diagnosis and management
Tuberculosis and HIV: key issues in diagnosis and management Julian Elliott Infectious Diseases Unit, Alfred Hospital Centre for Population Health, Burnet Institute julian.elliott@alfred.org.au Outline
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationRifabutin for TB for people on ART
Rifabutin for TB for people on ART Reuben Granich WHO HIV/AIDS Department HIV/TB Core Group Meeting Addis Ababa, Ethiopia, 11-12 November 2008 Towards Universal Treatment Access Gains in Access to Care
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationHIV and Malaria Interactions
HIV and Malaria Interactions Dr. Moses R. Kamya Chair and Professor of Medicine Makerere University College of Health Sciences Kampala, Uganda INTEREST, Mombasa, Kenya 8 th -11 th May 2012 1 Outline Brief
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationPediatric Antiretroviral Therapy
Update on Pediatric Antiretroviral Therapy Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health
More informationProgress and Challenges of Antiretroviral Medications. Preethi Raghavan RVD Pharmacist, Hospital Sungai Buloh
Progress and Challenges of Antiretroviral Medications Preethi Raghavan RVD Pharmacist, Hospital Sungai Buloh Learning Objectives After attending this presentation, participants will be able to: 1.Describe
More informationPrevention and Treatment of Selected Opportunistic Infections: A Guidelines Update
Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update Constance A. Benson, MD Professor of Medicine Division of Infectious Diseases University of California, San Diego Disclosures
More informationVitamin D Deficiency in HIV: A Shadow on Long-Term Management?
AIDS Rev. 2014;16:59-74 (Supplementary Data) Vitamin D Deficiency in HIV: A Shadow on Long-Term Management? Chloe Orkin, et al.: Vitamin D deficiency in HIV (Supplementary Data) Chloe Orkin 1, David A.
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTB/HIV management survey
TB/HIV management survey! Baseline audit in parallel with guidelines development process! Survey of clinician opinion and practice! Data collection from October 2004 to January 2005! Data was received
More informationNurse Case Management Phoenix, Arizona February 20-22, 2008
Nurse Case Management Phoenix, Arizona February 20-22, 2008 TB/HIV: Managing the Co-Infected Patient Adriana Vasquez, MD February 21, 2008 HIV Treatment Guidelines DHHS December 1,2007 TB/HIV Managing
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationIssues in TB Drug Development: TB/HIV
Issues in TB Drug Development: TB/HIV Open Forum Gavin Churchyard 18 th August 2010 Presentation outline TB/HIV Epidemiology clinical aspects HIV associated TB Drug-Drug interactions Immunotherapy Latent
More informationHistoric Perspective on HIV and TB Research in Pregnant Women
Historic Perspective on HIV and TB Research in Pregnant Women Lynne M. Mofenson, M.D. Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation High Burden of TB/HIV in Women - 2016 TB HIV
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationCo-infection in Thailand. Chiangrai Thailand
Treatment of TB-HIV Co-infection in Thailand Dr.Pacharee Kantipong M.D. 26 September 2008 Chiangrai Regional Hospital Chiangrai Thailand Presentation Outlines Situation of HIV, TB, TB/HIV; global, Thailand,
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationImmune Reconstitution Inflammatory Syndrome - IRIS
Immune Reconstitution Inflammatory Syndrome - IRIS Douglas G. Fish, MD Head, Division of HIV Medicine Albany Medical College Cali, Colombia March 25, 2010 I-Tech: Thank you International Training and
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationTB and HIV co-infection: when to start antiretroviral therapy
TB and HIV co-infection: when to start antiretroviral therapy Guidelines on when to start therapy in TB and HIV co-infection. Linda-Gail Bekker, MB ChB, DTMH, DCH, FCP(SA), PhD Robi Wood, BSc, BM, BCh,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationACTG A5221 STRIDE: An international randomized trial of immediate vs early antiretroviral therapy (ART) in HIV+ patients treated for tuberculosis
ACTG A5221 STRIDE: An international randomized trial of immediate vs early antiretroviral therapy (ART) in HIV+ patients treated for tuberculosis D Havlir, P Ive, M Kendall, A Luetkemeyer, S Swindells,
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationBritish Journal of Clinical Pharmacology. Daniel Atwine 1,2,4, Maryline Bonnet 1,3,4 and Anne-Marie Taburet 5,6
British Journal of Clinical Pharmacology Br J Clin Pharmacol (2018) 84 1641 1658 1641 SYSTEMATIC REVIEW AND META-ANALYSIS Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high
More informationPharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03220.x Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women Matthieu Roustit, 1,2 Malik Jlaiel, 1
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationComplications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome
SUPPLEMENT ARTICLE Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome Helen McIlleron, 1 Graeme Meintjes,
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More information2009 Revisions of WHO ART Guidelines. November 2009
2009 Revisions of WHO ART Guidelines November 2009 Guidelines Development Process 01/09 2009 WHO ART guideline revision process Scope of the work 03/09 WHO Guideline review committee approval 04/09 05/09
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More information